← All Brainstorm Cell Therapeutics INC filings

Brainstorm Cell Therapeutics INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

OQB
BCLI
Brainstorm Cell Therapeutics INC
10-K: Brainstorm Cell Therapeutics Faces Delisting, Pursues ALS Trial
Brainstorm Cell Therapeutics Inc. reports a net loss of $10.3 million for 2025, delisting from Nasdaq, and continues development of NurOwn for ALS despite past FDA setbacks.
OQB
BCLI
Brainstorm Cell Therapeutics INC
10-K: Brainstorm Cell Therapeutics Faces Financial Hurdles Despite NurOwn's Progress, Outlines Path Forward in Annual Report
Brainstorm Cell Therapeutics' 10-K filing reveals ongoing financial challenges and a strategic focus on advancing NurOwn for ALS through a planned Phase 3b trial, despite past regulatory setbacks.
OQB
BCLI
Brainstorm Cell Therapeutics INC
10-K: Brainstorm Cell Therapeutics Navigates Regulatory Hurdles, Outlines Path for Future ALS Trial
Brainstorm Cell Therapeutics withdrew its Biologics License Application (BLA) for NurOwn to treat ALS after an unfavorable advisory committee vote, but is moving forward with plans for a new Phase 3b trial.